Post-Marketing Surveillance of the Cinepazide Maleate Injection: a Real World Study

Study at a glance

From the registry record, last updated by the sponsor on 27 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title

Post-Marketing Surveillance of the Cinepazide Maleate Injection: a Real World Study

ClinicalTrials.gov ID

NCT01946919

Acronym / sponsor ID

PACER / PekingUTH-Pharmacy-002

Conditions

Adverse Drug Reaction, Cinepazide, Stroke

Keywords

Cinepazide, Adverse Drug Reaction, Safety, Real World Study

Study type

Observational

Recruitment status

Completed

Enrolment

18,260 participants (actual)

Lead sponsor

Peking University Third HospitalUniversity, hospital or other

Collaborators

Beijing Sihuan Pharmaceutical Co. Ltd., China Rehabilitation Research Center, Beijing Huaxin Hospital, Fu Xing Hospital, Capital Medical University, Dongfang Hospital Beijing University of Chinese Medicine, Dongzhimen Hospital, Beijing, Xuanwu Hospital, Beijing, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Southern Medical University, China, Guangzhou First People's Hospital, Panyu Hospital of Traditional Chinese Medicine, Second Affiliated Hospital of Guangzhou Medical University, The People's Hospital of Gaozhou, Zhongshan Hospital Of Traditional Chinese Medicine, Second Affiliated Hospital of Shantou University Medical College, Sun Yat-sen University, Central People's Hospital of Zhanjiang, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Tongji Hospital, Renmin Hospital of Wuhan University, Xiangya Hospital of Central South University, Second Xiangya Hospital of Central South University, The Third Xiangya Hospital of Central South University, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine, Changsha Third Hospital, Ankang City Central Hospital, Xijing Hospital, Tang-Du Hospital, First Affiliated Hospital Xi'an Jiaotong University, Gansu Provincial Hospital, LanZhou University, Qilu Hospital of Shandong University, Binzhou People's Hospital, Jiangxi Provincial People's Hopital, The First Affiliated Hospital of Nanchang University, Second Affiliated Hospital of Nanchang University, The Third Affiliated Hospital of Nanchang University, The Second Affiliated Hospital of Harbin Medical University, The Fourth Affiliated Hospital of Harbin Medical University, Second Affiliated Hospital of Heilongjiang University of Chinese Medicine, First People's Hospital of Shenyang, Jilin Provincial People's Hospital, Beihua University, Beijing Shijitan Hospital, Capital Medical University, Beijing Chuiyangliu Hospital, Longgang District People's Hospital of Shenzhen, Xi'an Central Hospital, Nanchang Third Hospital, First Affiliated Hospital of Harbin Medical University, First Affiliated Hospital of Heilongjiang Chinese Medicine University, Heilongjiang Provicial Hospital, First Hospital of China Medical University, No 202 hospital of PLA, The Fourth Affiliated Hospital of China Medical University, The General Hospital of Northern Theater Command, Central Hospital Affiliated to Shenyang Medical Collage, Wuhan Dongxihu District People's Hospital, 3201 Hospital, No 463 Hospital of PLA

Study start

Oct 2012

Primary completion

Dec 2021 (actual)

Study completion

Jun 2022 (actual)

First posted

20 Sep 2013 (estimated)

Results

Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Study design

Observational model

Cohort

Time perspective

Prospective

Target follow-up

14 Days

Number of arms

1

Who may qualify

Sex

All

Healthy volunteers

Not accepted

Age groups

Child, Adult, Older adult

Study population

Inpatient using the cinepazide in the department of neurology in 61 hospitals in China.

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Primary outcome

1. Incidence of adverse drug reaction of cinepazide in department of neurology

   Time frame: 1.5 years

Results and safety

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

Research links

• Official record on ClinicalTrials.govLast updated by the sponsor 27 Oct 2026.

Related trials for Adverse Drug Reaction

• Not yet recruitingPhase 2

  The Impact of Using Nicorandil for the Prevention of Doxorubicin-Induced Cardiotoxicity

  Doxorubicin Induced Cardiotoxicity, Doxorubicin Induced Cardiomyopathy

• Not yet recruiting

  Feasibility Study of Huangqi Yangyuan Formula for Capecitabine-Induced Adverse Reactions in Advanced Colorectal Cancer

  Advanced Colorectal Cancer, Capecitabine-Related Adverse Reaction

• RecruitingPhase 4

  Propofol-Ketamine Versus Sevoflurane for Laryngeal Mask Anesthesia in Pediatric Cardiac Catheterization

  Propofol, Ketamine

• Active, not recruiting

  Introducing Electronic Alerts to Reduce Inappropriate Digoxin Prescribing in Older Adults

  Drug-Related Side Effects and Adverse Reaction, Digoxin Overdose

• RecruitingObservational study

  Reduction of Adverse Drug Events and Readmissions

  Pharmacogenomic Testing for Medication Management

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

The record lists no contact. Use the official record to reach the sponsor.

61 sites in 1 country: see every site and its status.